All About ER Positive, HER2 Negative Breast Cancer

All About ER Positive, HER2 Negative Breast Cancer
About one in eight women in the United States will develop breast cancer, according to commonly used statistics. But other reports indicate that breast cancer rates are on the decline, likely because of improved recognition, prevention, and treatment. One advancement is the ability to identify different breast cancer types based on specific molecules found in tumors. The distinction greatly aids in breast cancer treatment selection and helps doctors predict how aggressive cancers will advance. A crucial step in the process of beast cancer evaluation is testing tumor tissue removed during a biopsy or surgery to determine if it has estrogen and progesterone receptors -  molecules that the hormones bind to. Cancerous cells may have none, one, or both receptors. Breast cancers that have estrogen receptors are called ER-positive (or ER+). Those with progesterone receptors are referred to as PR-positive (or PR+). In addition to hormone receptors, some breast cancers have high levels of a growth-promoting protein called HER2/neu. If a tumor has this property, it is called HER2-positive. HER2 positive cancers are more aggressive than HER2 negative cancer. Knowing breast cancer type, leads doctors to determining best treatments. For example; in ER positive/HER2 negative breast cancer, tumors that are ER positive are much more likely to respond to treatments that block estrogen. Treatment possibilities include selective estrogen-receptor response modulators (SERMs), aromatase inhibitors, estrogen-receptor downregulators (ERDs) and luteinizing hormone-releasing hormone agents (L
Subscribe or to access all post and page content.